SI9720047A - Nove spojine in sestavki za zdravljenje bolezni, povezanih z delovanjem triptaze - Google Patents

Nove spojine in sestavki za zdravljenje bolezni, povezanih z delovanjem triptaze Download PDF

Info

Publication number
SI9720047A
SI9720047A SI9720047A SI9720047A SI9720047A SI 9720047 A SI9720047 A SI 9720047A SI 9720047 A SI9720047 A SI 9720047A SI 9720047 A SI9720047 A SI 9720047A SI 9720047 A SI9720047 A SI 9720047A
Authority
SI
Slovenia
Prior art keywords
alkylene
compound
hetero
formula
piperazinecarboxylate
Prior art date
Application number
SI9720047A
Other languages
English (en)
Slovenian (sl)
Inventor
Jeffrey Mark Dener
Elaine Yee-Lin Kuo
Ken Duane Rice
Vivian Rueywen Wang
Wendy Beth Young
Original Assignee
Arris Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharmaceutical Corporation filed Critical Arris Pharmaceutical Corporation
Publication of SI9720047A publication Critical patent/SI9720047A/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI9720047A 1996-07-30 1997-07-30 Nove spojine in sestavki za zdravljenje bolezni, povezanih z delovanjem triptaze SI9720047A (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2313996P 1996-07-30 1996-07-30
US89577297A 1997-07-17 1997-07-17
PCT/US1997/013422 WO1998004537A1 (en) 1996-07-30 1997-07-30 Novel compounds and compositions for treating diseases associated with tryptase activity

Publications (1)

Publication Number Publication Date
SI9720047A true SI9720047A (sl) 1999-08-31

Family

ID=26696778

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9720047A SI9720047A (sl) 1996-07-30 1997-07-30 Nove spojine in sestavki za zdravljenje bolezni, povezanih z delovanjem triptaze

Country Status (17)

Country Link
EP (1) EP0934293A1 (lv)
JP (1) JP2001509787A (lv)
KR (1) KR20000029679A (lv)
CN (1) CN1073103C (lv)
AU (1) AU733621B2 (lv)
CA (1) CA2262542A1 (lv)
CZ (1) CZ29799A3 (lv)
EE (1) EE9900036A (lv)
FI (1) FI990171A (lv)
HU (1) HUP0003267A3 (lv)
LV (1) LV12291B (lv)
NO (1) NO990433L (lv)
NZ (1) NZ333713A (lv)
PL (1) PL331465A1 (lv)
SI (1) SI9720047A (lv)
SK (1) SK8599A3 (lv)
WO (1) WO1998004537A1 (lv)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
JP2002502845A (ja) * 1998-02-06 2002-01-29 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ トリプターゼ阻害物質
JP2002502850A (ja) * 1998-02-06 2002-01-29 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ トリプターゼ阻害物質
IL141654A0 (en) * 1998-09-04 2002-03-10 Byk Gulden Lomberg Chem Fab Pyranose derivatives and pharmaceutical compositions containing the same
IL147649A0 (en) 1999-08-10 2002-08-14 Byk Gulden Lomberg Chem Fab Tryptase inhibitors
JP2003509417A (ja) * 1999-09-14 2003-03-11 アルタナ ファルマ アクチエンゲゼルシャフト トリプターゼインヒビター
AU1413301A (en) * 1999-11-17 2001-05-30 Sumitomo Pharmaceuticals Company, Limited Diabetic remedy containing dipiperazine derivative
DE19955476A1 (de) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
AU783217B2 (en) * 1999-12-20 2005-10-06 Altana Pharma Ag Tryptase inhibitors
DE60011300T2 (de) 1999-12-20 2005-08-04 Altana Pharma Ag Inhibitoren der tryptase
JP2004517943A (ja) 2001-01-31 2004-06-17 アルタナ ファルマ アクチエンゲゼルシャフト ジアゾシン誘導体およびトリプターゼインヒビターとしてのその使用
JP2004518735A (ja) 2001-02-21 2004-06-24 アルタナ ファルマ アクチエンゲゼルシャフト トリプターゼインヒビター
DE60217076T2 (de) 2001-02-21 2007-06-21 Altana Pharma Ag Tryptaseinhibitoren
EP1370518A2 (en) * 2001-03-15 2003-12-17 ALTANA Pharma AG Tryptase-inhibitors
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
HUP0400167A3 (en) 2001-06-11 2012-09-28 Xenoport Inc Prodrugs of gaba analogs, compositions and uses thereof
ATE348803T1 (de) 2001-06-19 2007-01-15 Altana Pharma Ag Tryptase-inhibitoren
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
CN102159201A (zh) 2008-12-19 2011-08-17 莫茨药物股份两合公司 用于治疗肥大细胞介导的疾病的1-氨基-烷基环己烷衍生物
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之1-胺基-烷基環己烷衍生物類
FR3038605B1 (fr) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation
US20200199168A1 (en) * 2017-05-12 2020-06-25 Riken Class a gpcr-binding compound modifier

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
EP0688337A1 (en) * 1993-03-12 1995-12-27 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
US5656660A (en) * 1994-06-01 1997-08-12 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
CA2200561A1 (en) * 1994-09-23 1996-03-28 Ken D. Rice Compositions and methods for treating mast-cell inflammatory conditions
JPH11503417A (ja) * 1995-03-24 1999-03-26 アリス・ファーマシューティカル・コーポレイション 可逆的プロテアーゼインヒビター
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Also Published As

Publication number Publication date
SK8599A3 (en) 2000-03-13
FI990171A (fi) 1999-03-23
JP2001509787A (ja) 2001-07-24
NO990433L (no) 1999-03-25
WO1998004537A1 (en) 1998-02-05
FI990171A0 (fi) 1999-01-29
KR20000029679A (ko) 2000-05-25
EE9900036A (et) 1999-08-16
HUP0003267A3 (en) 2002-02-28
LV12291B (lv) 2000-04-20
CN1226892A (zh) 1999-08-25
AU3967097A (en) 1998-02-20
AU733621B2 (en) 2001-05-17
NO990433D0 (no) 1999-01-29
HUP0003267A2 (hu) 2001-06-28
CA2262542A1 (en) 1998-02-05
PL331465A1 (en) 1999-07-19
NZ333713A (en) 2000-12-22
CZ29799A3 (cs) 1999-06-16
EP0934293A1 (en) 1999-08-11
CN1073103C (zh) 2001-10-17
LV12291A (lv) 1999-06-20

Similar Documents

Publication Publication Date Title
SI9720047A (sl) Nove spojine in sestavki za zdravljenje bolezni, povezanih z delovanjem triptaze
US7932247B2 (en) M3 muscarinic acetylcholine receptor antagonists
US5677317A (en) Lactam compounds which are useful in the treatment of asthma
US20080139619A1 (en) Novel derivatives of benzimidazale and imidazo-pyridine and their use as medicaments
US20090142279A1 (en) Novel m3 muscarinic acetylcholine receptor antagonists
SI9520101A (en) Compositions and methods for treating mast-cell inflammatory condition
US7482468B2 (en) Imidazole and benzimidazole derivatives useful as histamine H3 antagonists
WO2000027826A1 (de) Neue pyrimidine, deren herstellung und verwendung
WO2000072834A9 (en) Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property
CZ20012562A3 (cs) Amidové sloučeniny
DE4243858A1 (de) Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1874739B1 (en) Pharmaceutically active diazepanes
EP1057815B1 (en) Cyclic amide compounds
US7015325B2 (en) Tryptase inhibitors
JP2013515725A (ja) [4[4−(5−アミノメチル−2−フルオロ−フェニル)−ピペリジン−1−イル]−(1h−ピロロ−ピリジン−イル)−メタノン類及びその合成
NZ506614A (en) Compounds for treating diseases associated with tryptase activity
MXPA99001105A (en) Novel compounds and compositions for treating diseases associated with tryptase activity
EP1789389A1 (en) Piperidine compound and process for preparing the same
LT4587B (lt) Nauji junginiai ir kompozicijos, skirti gydyti ligas, susijusias su triptazės aktyvumu
EP1368317B1 (en) Tryptase inhibitors
AU2002253035A1 (en) Tryptase inhibitors
LV12459B (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TRIPTASE ACTIVITY-RELATED DISEASES